Значения термина abbott 40566 на английском

The one most responsible for the mind-altering effects of the drug is called delta-9 tetrahydrocannabinol, or THC.

Conclusions.-: Most cases of vaping-associatedlung injury have been linked to vaping products containing tetrahydrocannabinol or other cannabinoids.

The bill passed on Tuesday envisages permitting use of products containing the psychoactive ingredient tetrahydrocannabinol (THC).

However, trials were limited by short duration, variability in dosing and strength of delta-9-tetrahydrocannabinol, and lack of functional outcomes.

The extract is low in tetrahydrocannabinol, or THC, the psychoactive compound that gives users the feeling of being high.

However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects.

HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects.

Conclusions: In HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake.

During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression.

Results: Despite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing.

Urine tests have a high likelihood of being positive after Marinol therapy.

Marinol A synthetic form of THC used to treat ailments like nausea and low appetite.

Patients taking the synthetic THC drug Marinol for nausea, for instance, often report nasty psychoactive side effects like paranoia.

THC doses (hemp oils with various THC concentrations and the therapeutic drug Marinol) were administered three times daily for 5 days.

In 1985, the FDA signed off on Marinol, which contains a synthetic version of THC, to treat loss of appetite in people with AIDS.

Data could not be pooled owing to heterogeneity in delta-9-tetrahydrocannabinol potency by dried weight, differing frequency and duration of treatment, and variability in assessing outcomes.

The CB1 cannabinoid receptor is targeted in the brain by endocannabinoids under physiological conditions as well as by delta9-tetrahydrocannabinol under cannabis use.

These findings suggest that low doses of 8-OHDPAT may improve delta9-tetrahydrocannabinol-induced impairment of spatial memory by enhancing acetylcholine release in the dorsal hippocampus.

These results suggest that anandamide-like cannabinoids may have a unique pharmacology that only partially overlaps with that of Delta9-tetrahydrocannabinol and other traditional cannabinoids.

Whereas pronounced tolerance develops to many of the in vivo pharmacological effects of Delta9-tetrahydrocannabinol with repeated dosing, tolerance to anandamide-induced effects is typically less noted.

These synergistic effects became obvious only months after the last Δ9-THC.

The combination of CBN and delta9-THC rather appeared to accentuate the drug response.

The psychoactive properties of marijuana are mediated by the active constituent, Delta(9)-THC, interacting primarily with CB1 cannabinoid receptors in a large number of brain areas.